Literature DB >> 19618813

Efficacy of a program to prevent beryllium sensitization among new employees at a copper-beryllium alloy processing facility.

Carrie A Thomas1, Rachel L Bailey, Michael S Kent, David C Deubner, Kathleen Kreiss, Christine R Schuler.   

Abstract

OBJECTIVES: In 2000, 7% of workers at a copper-beryllium facility were beryllium sensitized. Risk was associated with work near a wire annealing/pickling process. The facility then implemented a preventive program including particle migration control, respiratory and dermal protection, and process enclosure. We assessed the program's efficacy in preventing beryllium sensitization.
METHODS: In 2000, the facility began testing new hires (program workers) with beryllium lymphocyte proliferation tests (BeLPTs) at hire and at intervals during employment. We compared sensitization incidence rates (IRs) and prevalence rates for workers hired before the program (legacy workers) with rates for program workers, including program worker subgroups. We also examined trends in BeLPTs from a single laboratory.
RESULTS: In all, five of 43 legacy workers (IR = 3.8/1,000 person-months) and three of 82 program workers (IR = 1.9/1,000 person-months) were beryllium sensitized, for an incidence rate ratio (IRR) of 2.0 (95% confidence interval [CI] 0.5, 10.1). Two of 37 pre-enclosure program workers (IR = 2.4/1,000 person-months) and one of 45 post-enclosure program workers (IR = 1.4/1,000 person-months) were beryllium sensitized, for IRRs of 1.6 (95% CI 0.3, 11.9) and 2.8 (95% CI 0.4, 66.2), respectively, compared with legacy workers. Test for trend in prevalence rates was significant. Among 2,159 first-draw BeLPTs during 95 months, we identified seven months when high numbers of redraws were required, with one possible misclassification in this facility.
CONCLUSIONS: Fewer workers became sensitized after implementation of the preventive program. However, low statistical power due to the facility's small workforce prevents a definitive conclusion about the program's efficacy. These findings have implications for other copper-beryllium facilities, where program components may merit application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618813      PMCID: PMC2708662          DOI: 10.1177/00333549091244S113

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  26 in total

1.  CHRONIC BERYLLIUM DISEASE DUE TO LOW BERYLLIUM CONTENT ALLOYS.

Authors:  H L ISRAEL; D A COOPER
Journal:  Am Rev Respir Dis       Date:  1964-01

2.  Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites.

Authors:  Laura Welch; Knut Ringen; Eula Bingham; John Dement; Tim Takaro; William McGowan; Anna Chen; Patricia Quinn
Journal:  Am J Ind Med       Date:  2004-09       Impact factor: 2.214

3.  Keeping beryllium workers safe: an enhanced preventive model.

Authors:  David Deubner; Michael Kent
Journal:  J Occup Environ Hyg       Date:  2007-03       Impact factor: 2.155

4.  Cutaneous hypersensitivity due to beryllium; a study of thirteen cases.

Authors:  G H CURTIS
Journal:  AMA Arch Derm Syphilol       Date:  1951-10

5.  Possible health risks from low level exposure to beryllium.

Authors:  A W Stange; D E Hilmas; F J Furman
Journal:  Toxicology       Date:  1996-07-17       Impact factor: 4.221

6.  A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment.

Authors:  T Yoshida; S Shima; K Nagaoka; H Taniwaki; A Wada; H Kurita; K Morita
Journal:  Ind Health       Date:  1997-07       Impact factor: 2.179

7.  Respiratory disease associated with beryllium refining and alloy fabrication. 1968 follow-up.

Authors:  J Lieben; R R Williams
Journal:  J Occup Med       Date:  1969-09

8.  The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.

Authors:  Arthur W Stange; F Joseph Furman; Duane E Hilmas
Journal:  Am J Ind Med       Date:  2004-11       Impact factor: 2.214

Review 9.  Beryllium: a modern industrial hazard.

Authors:  Kathleen Kreiss; Gregory A Day; Christine R Schuler
Journal:  Annu Rev Public Health       Date:  2007       Impact factor: 21.981

10.  Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations.

Authors:  Holly M Sackett; Lisa A Maier; Lori J Silveira; Margaret M Mroz; Lorraine G Ogden; James R Murphy; Lee S Newman
Journal:  J Occup Environ Med       Date:  2004-09       Impact factor: 2.162

View more
  6 in total

Review 1.  The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.

Authors:  Stella E Hines; Karin Pacheco; Lisa A Maier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

2.  NIOSH's Respiratory Health Division: 50 years of science and service.

Authors:  Kristin J Cummings; Doug O Johns; Jacek M Mazurek; Frank J Hearl; David N Weissman
Journal:  Arch Environ Occup Health       Date:  2018-12-02       Impact factor: 1.663

3.  Interventions: advancing the state of the art.

Authors:  Lisa M Brosseau; David L Parker
Journal:  Public Health Rep       Date:  2009 Jul-Aug       Impact factor: 2.792

4.  Beryllium in urine by ICP-MS: a comparison of low level exposed workers and unexposed persons.

Authors:  Jackie Morton; Elizabeth Leese; Richard Cotton; Nicholas Warren; John Cocker
Journal:  Int Arch Occup Environ Health       Date:  2010-10-21       Impact factor: 3.015

5.  Migration of Beryllium via Multiple Exposure Pathways among Work Processes in Four Different Facilities.

Authors:  Jenna L Armstrong; Gregory A Day; Ji Young Park; Aleksandr B Stefaniak; Marcia L Stanton; David C Deubner; Michael S Kent; Christine R Schuler; M Abbas Virji
Journal:  J Occup Environ Hyg       Date:  2014       Impact factor: 2.155

6.  Associations of Metrics of Peak Inhalation Exposure and Skin Exposure Indices With Beryllium Sensitization at a Beryllium Manufacturing Facility.

Authors:  M Abbas Virji; Christine R Schuler; Jean Cox-Ganser; Marcia L Stanton; Michael S Kent; Kathleen Kreiss; Aleksandr B Stefaniak
Journal:  Ann Work Expo Health       Date:  2019-10-11       Impact factor: 2.179

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.